Poland· PL-100158011
Aprovel
A irbesartan product containing irbesartanum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 18 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Irbesartan is registered in 18 of 19 countries.
Countries holding a registration under ATC C09CA04 (irbesartan), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 11 of them publish a price we can compare per daily dose
Irbesartan · ATC C09CA04
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of irbesartan costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.14 in France to $0.68 in Switzerland — a ×4.7 gap.
- 5 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Irbesartan · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$0.68
- ES Spain$0.31
- IT Italy$0.26
- US United States$0.16 (acquisition cost)
- FR France$0.14
The record
At a glance
URPL (Poland)- Active substance
- Irbesartanum
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- C09CA04
- ATC class
- Irbesartan
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 8
- gtin05909990430307
- gtin05909990430321
- gtin05909990430338
- gtin05909990430345
- gtin05909990430352
- gtin05909990955954
- gtin05909990955961
- gtin05909990955978
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
371 interactions on record for irbesartan.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Irbesartan · interactions on record
371 records
- 7 severe
- 128 moderate
- 3 minor
- 152 info
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium gluconateA12BA05severe
- Potassium chlorideB05XA01severe
81 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Irbesartan in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAPROVELSanofi Winthrop Industrie, Gentilly
- SpainAPROVEL 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULASanofi Winthrop Industrie
- BelgiumAprexevo 150 mg - 5 mgSanofi Belgium
- ItalyABESARTGENETIC S.P.A.
- FinlandAprovelSanofi Winthrop Industrie
- FranceAPROVEL 150 mg, comprimé pelliculéSANOFI WINTHROP INDUSTRIE
- NetherlandsAprovel 150 mg, filmomhulde tablettenSanofi Winthrop Industrie
- SwitzerlandAprovel 150
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Irbepress, Irbesartan Hexal
- Belgium · Irbesartan Eg, Irbesartan Sandoz
- Bulgaria · Ирбесан, Ирбесо
- Cyprus · Converium, Irbesartan Vocate
- Czechia · Isame
- Germany · Irbepress, Irbesartan 1 A Pharma
- Denmark · Irbesartan Accord, Irbesartan Jubilant
- Spain · Irbesartán Almus, Irbesartán Alter
- France · Irbesartan Accord, Irbesartan Arrow
- United Kingdom (Northern Ireland) · Irbesartan, Irbesartan Accord
- Greece · Besartan, Irbegen
- Hungary · Irabel, Irbesartan Sandoz
- Ireland · Irbesartan Clonmel, Irbesartan Rowa
- Iceland · Aprovel, Ifirmasta
- Italy · Abesart, Irbesartan Accord
- Liechtenstein · Aprovel, Irbesartan Teva
- Luxembourg · Irbesartan Eg, Irbesartan Viatris
- Malta · Irbesartan Aurobindo Pharma (Malta)
- Netherlands · Artibesan, Irbesartan Accord
- Norway · Aprovel, Ifirmasta
- Portugal · Irbesartan Alter, Irbesartan Aurovitas
- Romania · Irbesartan Terapia
- Sweden · Irbesartan Accord, Irbesartan Actavis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a4ec81c-7fc0-4773-84f1-95ef85cb5a5e GET /v1/drugs/0a4ec81c-7fc0-4773-84f1-95ef85cb5a5e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "150 mg",
"packaging": "05909990430307 ¦ Rp ¦ EU/1/97/046/021 ¦ 31937\n14 tabl.\n05909990430321 ¦ Rp ¦ EU/1/97/046/022 ¦ 31938\n28 tabl.\n05909990430338 ¦ Rp ¦ EU/1/97/046/023 ¦ 31939\n56 tabl.\n05909990430345 ¦ Rp ¦ EU/1/97/046/024 ¦ 31940\n56 tabl. (56 x 1)\n05909990430352 ¦ Rp ¦ EU/1/97/046/025 ¦ 31941\n98 tabl.\n05909990955954 ¦ Rp ¦ EU/1/97/046/032 ¦ 74488\n84 tabl.\n05909990955961 ¦ Rp ¦ EU/1/97/046/035 ¦ 74489\n30 tabl.\n05909990955978 ¦ Rp ¦ EU/1/97/046/038 ¦ 74490\n90 tabl.",
"substance": "Irbesartanum 150 mg",
"common_name": "Irbesartanum",
"pl_product_id": "100158011",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about irbesartan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.